{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T04:10:43Z","timestamp":1728706243867},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,11]]},"DOI":"10.7759\/cureus.71266","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T16:37:34Z","timestamp":1728664654000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Nanoparticle Loteprednol Etabonate Compared to Vehicle in Post-cataract Surgery Pain and Anterior Chamber Inflammation Management: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Hatem M","family":"Alsolami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali S","family":"Alsudais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad H","family":"Nooh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basel M","family":"Alsolami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed M","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naif","family":"Almufarriji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed A","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2015.05.012","article-title":"Cataracts","volume":"42","author":"Thompson J","year":"2015","unstructured":"Thompson J, Lakhani N. Cataracts. Prim Care. 2015, 42:409-23. 10.1016\/j.pop.2015.05.012","journal-title":"Prim Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7559.128","article-title":"Cataract and surgery for cataract","volume":"333","author":"Allen D","year":"2006","unstructured":"Allen D, Vasavada A. Cataract and surgery for cataract. BMJ. 2006, 333:128-32. 10.1136\/bmj.333.7559.128","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17911-2","article-title":"Age-related cataract","volume":"365","author":"Asbell PA","year":"2005","unstructured":"Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract. Lancet. 2005, 365:599-609. 10.1016\/S0140-6736(05)17911-2","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aopr.2021.100008","article-title":"Cataract: advances in surgery and whether surgery remains the only treatment in future","volume":"1","author":"Chen X","year":"2021","unstructured":"Chen X, Xu J, Chen X, Yao K. Cataract: advances in surgery and whether surgery remains the only treatment in future. Adv Ophthalmol Pract Res. 2021, 1:100008. 10.1016\/j.aopr.2021.100008","journal-title":"Adv Ophthalmol Pract Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0886-3350(01)01185-3","article-title":"Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study","volume":"28","author":"Holzer MP","year":"2002","unstructured":"Holzer MP, Solomon KD, Sandoval HP, Vroman DT. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J Cataract Refract Surg. 2002, 28:93-9. 10.1016\/s0886-3350(01)01185-3","journal-title":"J Cataract Refract Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2012.10.039","article-title":"Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery","volume":"39","author":"Lane SS","year":"2013","unstructured":"Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013, 39:168-73. 10.1016\/j.jcrs.2012.10.039","journal-title":"J Cataract Refract Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-1960","article-title":"Advances in pharmacotherapy of cataracts","volume":"8","author":"Xu J","year":"2020","unstructured":"Xu J, Fu Q, Chen X, Yao K. Advances in pharmacotherapy of cataracts. Ann Transl Med. 2020, 8:1552. 10.21037\/atm-20-1960","journal-title":"Ann Transl Med"},{"key":"ref8","article-title":"[Effect of 0.1% diclofenac ophthalmic solution on\u00a0inflammatory response and macular thickness following phacoemulsification cataract surgery]","volume":"118","author":"Zieli\u0144ska E","year":"2016","unstructured":"Zieli\u0144ska E, Rokicki D, Wielg\u00f3rski M, Szaflik J, Szaflik JP. [Effect of 0.1% diclofenac ophthalmic solution on\u00a0inflammatory response and macular thickness following phacoemulsification cataract surgery]. Klin Oczna. 2016, 118:270-7.","journal-title":"Klin Oczna"},{"key":"ref9","article-title":"Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain","volume":"25","author":"Salinger CL","year":"2019","unstructured":"Salinger CL, Gaynes BI, Rajpal RK. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. Am J Manag Care. 2019, 25:215.","journal-title":"Am J Manag Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.06.056","article-title":"Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery","volume":"44","author":"Fong R","year":"2018","unstructured":"Fong R, Silverstein BE, Peace JH, Williams JI, Vittitow JL. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery. J Cataract Refract Surg. 2018, 44:1220-9. 10.1016\/j.jcrs.2018.06.056","journal-title":"J Cataract Refract Surg"},{"key":"ref11","unstructured":"Identifier NCT01996839, Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery. (2013). Accessed. 2023 Mar 12: https:\/\/clinicaltrials.gov\/study\/NCT01996839."},{"key":"ref12","unstructured":"Identifier NCT02786901, LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery. (2016). Accessed. 2023 Mar 12: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02786901."},{"key":"ref13","unstructured":"Identifier NCT02163824, Safety and Efficacy of KPI-121 in Subjects with Postsurgical Inflammation (Hawaii-1). (2014). Accessed. 2023 Mar 15: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02163824."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies","volume":"40","author":"Korenfeld M","year":"2021","unstructured":"Korenfeld M, Nichols KK, Goldberg D, et al.. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. 2021, 40:564-70. 10.1097\/ICO.0000000000002452","journal-title":"Cornea"},{"key":"ref15","unstructured":"Identifier NCT02208297, Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery. (2015). Accessed. 2023 Mar 16: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02208297."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem H","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al.. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011, 64:401-6. 10.1016\/j.jclinepi.2010.07.015","journal-title":"J Clin Epidemiol"},{"key":"ref18","article-title":"Chapter 14: Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann HJ","year":"2023","unstructured":"Sch\u00fcnemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (ed): Cochrane, 2023."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835b0716","article-title":"Postoperative care in cataract surgery","volume":"24","author":"Shoss BL","year":"2013","unstructured":"Shoss BL, Tsai LM. Postoperative care in cataract surgery. Curr Opin Ophthalmol. 2013, 24:66-73. 10.1097\/ICU.0b013e32835b0716","journal-title":"Curr Opin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.035","article-title":"Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review","volume":"121","author":"Kessel L","year":"2014","unstructured":"Kessel L, Tendal B, J\u00f8rgensen KJ, Erngaard D, Flesner P, Andresen JL, Hjortdal J. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014, 121:1915-24. 10.1016\/j.ophtha.2014.04.035","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-013-0020-5","article-title":"Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?","volume":"2","author":"Pleyer U","year":"2013","unstructured":"Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?. Ophthalmol Ther. 2013, 2:55-72. 10.1007\/s40123-013-0020-5","journal-title":"Ophthalmol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2498-y","article-title":"Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations","volume":"35","author":"Shen J","year":"2018","unstructured":"Shen J, Lu GW, Hughes P. Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations. Pharm Res. 2018, 35:217. 10.1007\/s11095-018-2498-y","journal-title":"Pharm Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S361146","article-title":"Real-world experience with intracapsular administration of dexamethasone intraocular suspension 9% for control of postoperative inflammation","volume":"16","author":"McCabe C","year":"2022","unstructured":"McCabe C, Desai P, Nijmet L. Real-world experience with intracapsular administration of dexamethasone intraocular suspension 9% for control of postoperative inflammation. Clin Ophthalmol. 2022, 16:1985-92. 10.2147\/OPTH.S361146","journal-title":"Clin Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.018","article-title":"Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases","volume":"354","author":"Onugwu AL","year":"2023","unstructured":"Onugwu AL, Nwagwu CS, Onugwu OS, et al.. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release. 2023, 354:465-88. 10.1016\/j.jconrel.2023.01.018","journal-title":"J Control Release"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0073-8","article-title":"Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery","volume":"73","author":"Lyseng-Williamson KA","year":"2013","unstructured":"Lyseng-Williamson KA. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery. Drugs. 2013, 73:949-58. 10.1007\/s40265-013-0073-8","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-012-9589-2","article-title":"Loteprednol etabonate ophthalmic suspension 0.5\u00a0%: efficacy and safety for postoperative anti-inflammatory use","volume":"32","author":"Amon M","year":"2012","unstructured":"Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5\u00a0%: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012, 32:507-17. 10.1007\/s10792-012-9589-2","journal-title":"Int Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000407","article-title":"Comparison of efficacy of difluprednate 0.05% and loteprednol gel 0.5% after cataract surgery","volume":"44 Suppl 2","author":"Abessi B","year":"2018","unstructured":"Abessi B, Brooksby L, Schultze RL. Comparison of efficacy of difluprednate 0.05% and loteprednol gel 0.5% after cataract surgery. Eye Contact Lens. 2018, 44 Suppl 2:S37-42. 10.1097\/ICL.0000000000000407","journal-title":"Eye Contact Lens"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S32643","article-title":"Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial","volume":"6","author":"Fong R","year":"2012","unstructured":"Fong R, Leitritz M, Siou-Mermet R, Erb T. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012, 6:1113-24. 10.2147\/OPTH.S32643","journal-title":"Clin Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0059-7","article-title":"Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies","volume":"30","author":"Rajpal RK","year":"2013","unstructured":"Rajpal RK, Fong R, Comstock TL. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies. Adv Ther. 2013, 30:907-23. 10.1007\/s12325-013-0059-7","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S16832","article-title":"Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery","volume":"5","author":"Comstock TL","year":"2011","unstructured":"Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011, 5:177-86. 10.2147\/OPTH.S16832","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/294326-efficacy-and-safety-of-nanoparticle-loteprednol-etabonate-compared-to-vehicle-in-post-cataract-surgery-pain-and-anterior-chamber-inflammation-management-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T16:37:38Z","timestamp":1728664658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/294326-efficacy-and-safety-of-nanoparticle-loteprednol-etabonate-compared-to-vehicle-in-post-cataract-surgery-pain-and-anterior-chamber-inflammation-management-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.71266","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}